Biomolecules & Therapeutics

  • 제21권3호
  • /
  • Pages.190-195
  • /
  • 2013
  • /
  • 1976-9148(pISSN)
  • /
  • 2005-4483(eISSN)
한국응용약물학회 (The Korean Society of Applied Pharmacology)
권호 표지
DOI QR코드

DOI QR Code

Annexin A5 as a New Potential Biomarker for Cisplatin-Induced Toxicity in Human Kidney Epithelial Cells

  • 투고 : 2013.04.05
  • 심사 : 2013.05.14
  • 발행 : 2013.05.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Cisplatin is a member of platinum-containing anti-cancer drugs that causes cross-linking of DNA and ultimately cancer cell apoptosis. The therapeutic function of cisplatin on various types of cancers has been widely reported but the side effects have been discovered together and nephrotoxicity has been regarded as major side effect of cisplatin. To select candidates for new sensitive nephrotoxicity biomarker, we performed proteomic analysis using 2-DE/MALDI-TOF-MS followed by cisplatin treatment in human kidney cell line, HK-2 cells, and compared the results to the gene profile from microarray composed of genes changed in expression by cisplatin from formerly reported article. Annexin A5 has been selected to be the most potential candidate and it has been identified using Western blot, RT-PCR and cell viability assay whether annexin A5 is available to be a sensitive nephrotoxic biomarker. Treatment with cisplatin on HK-2 cells caused the increase of annexin A5 expression in protein and mRNA levels. Over-expression of annexin A5 blocked HK-2 cell proliferation, indicating correlation between annexin A5 and renal cell toxicity. Taken together, these results suggest the possibility of annexin A5 as a new biomarker for cisplatin-mediated nephrotoxicity.

키워드

참고문헌

  1. Damia, G., Filiberti, L., Vikhanskaya, F., Carrassa, L., Taya, Y., D'Incalci, M. and Broggini, M. (2001) Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia 3, 10-16. https://doi.org/10.1038/sj.neo.7900122
  2. Devarajan, P. (2007) Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle. Cancer Ther. 5, 463-470.
  3. Donzelli, E., Carfi , M., Miloso, M., Strada, A., Galbiati, S., Bayssas, M., Griffon-Etienne, G., Cavaletti, G., Petruccioli, M. G. and Tredici, G. (2004) Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. J. Neurooncol. 67, 65-73. https://doi.org/10.1023/B:NEON.0000021787.70029.ce
  4. Dreier, R., Schmid, K. W., Gerke, V. and Riehemann, K. (1998) Differential expression of annexins I, II and IV in human tissues: an immunohistochemical study. Histochem. Cell Biol. 110, 137-148. https://doi.org/10.1007/s004180050275
  5. Ea, H. K., Monceau, V., Camors, E., Cohen-Solal, M., Charlemagne, D. and Liote, F. (2008) Annexin 5 overexpression increased articular chondrocyte apoptosis induced by basic calcium phosphate crystals. Ann. Rheum. Dis. 67, 1617-1625. https://doi.org/10.1136/ard.2008.087718
  6. Fernandez, J., Gharahdaghi, F. and Mische, S. M. (1998) Routine identifi cation of proteins from sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels or polyvinyl difl uoride membranes using matrix assisted laser desorption/ionization-time of fl ight-mass spectrometry (MALDI-TOF-MS). Electrophoresis 19, 1036-1045. https://doi.org/10.1002/elps.1150190619
  7. Franke, R. M., Kosloske, A. M., Lancaster, C. S., Filipski, K. K., Hu, C., Zolk, O., Mathijssen, R. H. and Sparreboom, A. (2010) Influence of Oct1/Oct2-defi ciency on cisplatin-induced changes in urinary Nacetyl-beta-D-glucosaminidase. Clin. Cancer. Res. 16, 4198-4206. https://doi.org/10.1158/1078-0432.CCR-10-0949
  8. Hanigan, M. H. and Devarajan, P. (2003) Cisplatin nephrotoxicity: molecular mechanisms. Cancer Ther. 1, 47-61.
  9. Harmers, F. P., Gispen, W. H. and Neijt, J. P. (1991) Neurotoxic sideeffects of cisplatin. Eur. J. Cancer 27, 372-376. https://doi.org/10.1016/0277-5379(91)90549-S
  10. Kenis, H., Hofstra, L. and Reutelingsperger, C. P. (2007) Annexin A5: shifting from a diagnostic towards a therapeutic realm. Cell. Mol. Life Sci. 64, 2859-2862. https://doi.org/10.1007/s00018-007-7297-2
  11. Kenis, H., van Genderen, H., Bennaghmouch, A., Rinia, H. A., Frederik, P., Narula, J., Hofstra, L. and Reutelingsperger, C. P. (2004) Cell surface-expressed phosphatidylserine and annexin A5 open a novel portal of cell entry. J. Biol. Chem. 279, 52623-52629. https://doi.org/10.1074/jbc.M409009200
  12. Laurell, G. and Jungnelius, U. (1990) High-dose cisplatin treatment: hearing loss and plasma concentrations. Laryngoscope 100, 724-734.
  13. Lokich, J. and Anderson, N. (1998) Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann. Oncol. 9, 13-21.
  14. Markoff, A. and Gerke, V. (2005) Expression and functions of annexins in the kidney. Am. J. Physiol. 289, F949-956.
  15. Matsuda, R., Kaneko, N., Horikawa, Y., Chiwaki, F., Shinozaki, M., Abe, S., Yumura, W., Nihei, H. and Ieiri, T. (2000) Measurement of urinary annexin V by ELISA and its signifi cance as a new urinarymarker of kidney disease. Clin. Chim. Acta 298, 29-43. https://doi.org/10.1016/S0009-8981(00)00218-7
  16. Moss, S. E. and Morgan, R. O. (2004) The annexins. Genome Biol. 5, 219. https://doi.org/10.1186/gb-2004-5-4-219
  17. Pepinsky, R. B., Tizard, R., Mattaliano, R. J., Sinclair, L. K., Miller, G. T., Browning, J. L., Chow, E. P., Burne, C., Huang, K. S., Pratt, D., Wachter, L., Hession, C., Frey, A. Z. and Wallner, B. P. (1988) Five distinct calcium and phospholipid binding proteins share homology with lipocortin I. J. Biol. Chem. 263, 10799-10811.
  18. Prestayko, A. W., D'Aoust, J. C., Issell, B. F. and Crooke, S. T. (1979) Cisplatin (cis-diamminedichloroplatinum II). Cancer Treat. Rev. 6, 17-39. https://doi.org/10.1016/S0305-7372(79)80057-2
  19. Quasthoff, S. and Hartung, H. P. (2002) Chemotherapy-induced peripheral neuropathy. J. Neurol. 249, 9-17. https://doi.org/10.1007/PL00007853
  20. Raynal, P. and Pollard, H. B. (1994) Annexins: the problem of assessing the biological role for a gene family of multifunctional calciumand phospholipid-binding proteins. Biochim. Biophys. Acta 1197, 63-93. https://doi.org/10.1016/0304-4157(94)90019-1
  21. Reviakine, I., Bergsma-Schutter, W., Mazeres-Dubut, C., Govorukhina, N. and Brisson, A. (2000) Surface topography of the p3 and p6 annexin V crystal forms determined by atomic force microscopy. J. Struct. Biol. 131, 234-239. https://doi.org/10.1006/jsbi.2000.4286
  22. Sherman, S. E. and Lippard, S. J. (1987) Structural aspects of platinum anticancer drug-interactions with DNA. Chem. Rev. 87, 1153-1181. https://doi.org/10.1021/cr00081a013
  23. Siddik, Z. H. (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279. https://doi.org/10.1038/sj.onc.1206933
  24. Treskes, M. and van der Vijgh, W. J. (1993) WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother. Pharmacol. 33, 93-106. https://doi.org/10.1007/BF00685326
  25. Ungethum, L., Kenis, H., Nicolaes, G. A., Autin, L., Stoilova-McPhie, S. and Reutelingsperger, C. P. (2011) Engineered annexin A5 variants have impaired cell entry for molecular imaging of apoptosis using pretargeting strategies. J. Biol. Chem. 286, 1903-1910. https://doi.org/10.1074/jbc.M110.163527
  26. van den Eijnde, S. M., Luijsterburg, A. J., Boshart, L., De Zeeuw, C. I., van Dierendonck, J. H., Reutelingsperger, C. P. and Vermeij-Keers, C. (1997) In situ detection of apoptosis during embryogenesis with annexin V: from whole mount to ultrastructure. Cytometry 29, 313-320. https://doi.org/10.1002/(SICI)1097-0320(19971201)29:4<313::AID-CYTO8>3.0.CO;2-A
  27. Vermes, I., Haanen, C., Steffens-Nakken, H. and Reutelingsperger, C. (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fl uorescein labelled Annexin V. J. Immunol. Methods 184, 39-51. https://doi.org/10.1016/0022-1759(95)00072-I
  28. Wang, E. J., Snyder, R. D., Fielden, M. R., Smith, R. J. and Gu, Y. Z. (2008) Validation of putative genomic biomarkers of nephrotoxicity in rats. Toxicology 246, 91-100. https://doi.org/10.1016/j.tox.2007.12.031
  29. Wang, X., Martindale, J. L. and Holbrook, N. J. (2000) Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. 275, 39435-39443. https://doi.org/10.1074/jbc.M004583200
  30. Yamashita, T., Nagano, K., Kanasaki, S., Maeda, Y., Furuya, T., Inoue, M., Nabeshi, H., Yoshikawa, T., Yoshioka, Y., Itoh, N., Abe, Y., Kamada, H., Tsutsumi, Y. and Tsunoda, S. (2012) Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells. Biochem. Biophys. Res. Commun. 421, 140-144. https://doi.org/10.1016/j.bbrc.2012.03.144
  31. Yao, X., Panichpisal, K., Kurtzman, N. and Nugent, K. (2007) Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 334, 115-124. https://doi.org/10.1097/MAJ.0b013e31812dfe1e

피인용 문헌

  1. IKKβ-Targeted Anti-Inflammatory Activities of a Butanol Fraction of Artificially CultivatedCordyceps pruinosaFruit Bodies vol.2014, 2014, https://doi.org/10.1155/2014/562467
  2. Auranofin Promotes Mitochondrial Apoptosis by Inducing Annexin A5 Expression and Translocation in Human Prostate Cancer Cells vol.77, pp.22-24, 2014, https://doi.org/10.1080/15287394.2014.955834
  3. Recombinant Human Annexin A5 Can Repair the Disrupted Cardiomyocyte Adherens Junctions in Endotoxemia vol.44, pp.1, 2015, https://doi.org/10.1097/SHK.0000000000000370
  4. Ginsenoside-Rp1-induced apolipoprotein A-1 expression in the LoVo human colon cancer cell line vol.38, pp.4, 2014, https://doi.org/10.1016/j.jgr.2014.06.003
  5. Role of Annexin A5 on Mitochondria-Dependent Apoptosis Induced by Tetramethoxystilbene in Human Breast Cancer Cells vol.22, pp.6, 2014, https://doi.org/10.4062/biomolther.2014.112
  6. The Neuroprotective Role of MiR-124-3p in a 6-Hydroxydopamine-Induced Cell Model of Parkinson's Disease via the Regulation of ANAX5 2018, https://doi.org/10.1002/jcb.26170
  7. Nitric oxide- and cisplatin-releasing silica nanoparticles for use against non-small cell lung cancer vol.153, 2015, https://doi.org/10.1016/j.jinorgbio.2015.09.002
  8. Characterization of pig sperm hyaluronidase and improvement of the digestibility of cumulus cell mass by recombinant pSPAM1 hyaluronidase in an in vitro fertilization assay vol.150, pp.3-4, 2014, https://doi.org/10.1016/j.anireprosci.2014.09.002
  9. Auranofin Suppresses Plasminogen Activator Inhibitor-2 Expression through Annexin A5 Induction in Human Prostate Cancer Cells vol.25, pp.2, 2017, https://doi.org/10.4062/biomolther.2016.223
  10. Methanol Extract in Its Anti-Inflammatory Action vol.2018, pp.1741-4288, 2018, https://doi.org/10.1155/2018/3909038
  11. Treatment with Phytoestrogens Reversed Triclosan and Bisphenol A-Induced Anti-Apoptosis in Breast Cancer Cells vol.26, pp.5, 2018, https://doi.org/10.4062/biomolther.2017.160
  12. Methylglyoxal and D-lactate in cisplatin-induced acute kidney injury: Investigation of the potential mechanism via fluorogenic derivatization liquid chromatography-tandem mass spectrometry (FD-LC-MS/M vol.15, pp.7, 2013, https://doi.org/10.1371/journal.pone.0235849
  13. The protective effect of protocatechuic acid on hepatotoxicity induced by cisplatin in mice vol.277, pp.None, 2013, https://doi.org/10.1016/j.lfs.2021.119485